Antonio Vitale, Donato Rigante, Giuseppe Lopalco, Giacomo Emmi, Maria Teresa Bianco, Mauro Galeazzi, Florenzo Iannone, Luca Cantarini
INTRODUCTION: Behçet's syndrome (BS) is a systemic inflammatory disorder characterized by a wide range of potential clinical manifestations with no gold-standard therapy. However, the recent classification of BS at a crossroads between autoimmune and autoinflammatory syndromes has paved the way to new further therapeutic opportunities in addition to anti-tumor necrosis factor agents. AREAS COVERED: This review provides a digest of all current experience and evidence about pharmacological agents recently described as having a role in the treatment of BS, including interleukin (IL)-1 inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon-alpha-2a, and apremilast...
July 2016: Expert Opinion on Investigational Drugs